Association Between Serum Interleukin-32 Level and Disease Status in Cases with Neuromyelitis Optica Spectrum Disorders
Hong-Fei Yu,Jin Xu,Yi Fang,Lian-Chen Xiao
DOI: https://doi.org/10.2147/jir.s476435
IF: 4.5
2024-08-27
Journal of Inflammation Research
Abstract:Hong-Fei Yu, &ast Jin Xu, &ast Yi Fang, Lian-Chen Xiao Department of Neurology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lian-Chen Xiao; Yi Fang, Department of Neurology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, No. 136, Jingzhou Road, Xiangyang, People's Republic of China, Email ; Background: Various cytokines are involved in the pathogenesis of neuromyelitis optica spectrum disorders (NMOSD), but whether serum interleukin-32 (IL-32) level is related to disease activity in cases with NMOSD remains poorly understood. Thus, we investigated the underlying role of IL-32 in NMOSD cases. Methods: Our observation recruited 32 cases with acute NMOSD, 36 NMOSD cases in remission, and 60 healthy individuals in this study. Serum concentrations of IL-32 were detected using ELISA. The associations among IL-32 levels and clinical characteristics were assessed by Spearman correlation coefficient and logistic regression analysis. Results: IL-32 concentrations were strongly increased in cases with acute NMOSD [(52.06 ± 16.56) pg/mL] and NMOSD in remission [(25.78 ± 8.31) pg/mL] compared with healthy controls [(10.83 ± 6.94) pg/mL] (all p < 0.001). ROC analysis suggested that the AUC for IL-32 and the combined diagnosis of acute NMOSD was 0.811 ( P = 0.026, 95% CI 0.673– 0.949), with a sensitivity of 0.800 and a specificity of 0.806. The level of IL-32 was positively correlated with EDSS scores in patients with acute NMOSD (r = 0.620, p < 0.001). EDSS score was independently associated with increased serum levels of LI-32 (B = 1.529, p < 0.001). Conclusion: Higher level of IL-32 is related to disease severity in NMOSD. Therefore, serum IL-32 may be a novel biomarker for acute NMOSD. Keywords: IL-32, neuromyelitis optica spectrum disorders, biomarker Neuromyelitis optica spectrum disorder (NMOSD) is a chronic inflammatory disorder of CNS characterized by optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM). 1 It has been reported that 80% NMOSD cases are positive for aquaporin-4 (AQP4) immunoglobulin G antibodies, which leads to astrocyte damage, inflammatory cell infiltration, and myelin loss. 2 In 2015, the Wingerchuk group reported the first diagnostic criteria for NMOSD. 3 Thus, increasing number of patients with NMOSD are being diagnosed according to the latest diagnostic criteria. Nevertheless, the complex pathogenesis of NMOSD has not been fully uncovered. The main pathology of NMOSD involves in AQP4-IgG and lymphocyte function. AQP4-Ig penetrates the blood-brain barrier (BBB) and reacts with AQP4 in astrocyte, followed by recruiting and activating complement to trigger complement-dependent-cytotoxicity. Moreover, the AQP4-specific T-cells and B cell immuno-regulatory dysfunction may destroy the BBB and recruit sustained levels of pathogenic effectors in NMOSD. 4 Many studies have revealed that various inflammatory factors (IL-17A, IL-6, IL-22, or IL-35) and chemokines (CXCL8 or CXCL10) participate in the autoimmune response and CNS injury. 4,5 However, few researches have reported the association among IL-32 and clinical characteristics of cases with NMOSD. IL-32 plays an important role in the pathogenesis of immune-associated chronic inflammatory disorder. 6 It stimulates the production of various pro-inflammatory factors, including IL-1β and IL-6. IL-32 overexpression has been investigated in many autoimmune disorders, including arthritis, 7 asthma, 8 and myasthenia gravis. 9 IL-32 induces the maturation and activation of dendritic cells (DCs), thereby mediating Th1 and Th17 cell-associated immune response by secreting IL-12 and IL-6 through the NF-κB pathway. 10 Meanwhile, some researchers reported increased plasma levels of IL-32 in patients with NMOSD. 11 Nevertheless, the correlations among IL-32 levels and clinical variables in NMOSD cases have not been investigated. We assessed IL-32 levels in cases with acute and remitted NMOSD. We also investigated whether IL-32 level is related to disease severity in cases and whether it is a sensitive biomarker for NMOSD. This was a cross-section study conducted at Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science. In total, 68 patients, 32 with acute NMOSD and 36 with remitted NMOSD, were consecutively enrolled from July 2020 to Mar 2023. The inclusion criteria were adopted according to previous report. 3 Patients inclu -Abstract Truncated-
immunology